|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1996
gptkb:FDA
|
|
gptkbp:atccode
|
L01 CD02
|
|
gptkbp:brand
|
gptkb:docetaxel
|
|
gptkbp:can_be_combined_with
|
gptkb:cisplatin
gptkb:carboplatin
gptkb:doxorubicin
|
|
gptkbp:casnumber
|
114977-28-5
|
|
gptkbp:chemical_formula
|
C43 H53 N3 O14 S
|
|
gptkbp:class
|
gptkb:taxanes
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:contraindication
|
severe liver impairment
neutrophil count less than 1500/mm³
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulation
|
concentrate for solution for infusion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Taxotere
|
|
gptkbp:indication
|
gptkb:Oncology
gptkb:Kaposi's_sarcoma
ovarian cancer
esophageal cancer
bladder cancer
head and neck cancer
neuroendocrine tumors
gastric adenocarcinoma
|
|
gptkbp:ingredients
|
gptkb:docetaxel
|
|
gptkbp:is_monitored_by
|
liver function tests
blood counts
|
|
gptkbp:lifespan
|
35 hours
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:mechanism_of_action
|
inhibits microtubule depolymerization
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:safety_measures
|
risk of infection
risk of bleeding
risk of severe allergic reactions
risk of fluid retention
|
|
gptkbp:side_effect
|
fatigue
nausea
hair loss
low blood cell counts
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
treating breast cancer
treating prostate cancer
treating lung cancer
|
|
gptkbp:weight
|
807.95 g/mol
|
|
gptkbp:bfsParent
|
gptkb:docetaxel
|
|
gptkbp:bfsLayer
|
6
|